In the discussions and debates around the optimal breast cancer screening strategies, overdiagnosis and overtreatment concerns loom large. Now, a study published in JAMA Oncology might be cause to reevaluate the detection and treatment of ductal carcinoma in situ (DCIS), or stage 0 cancer.

NeuroLogica, a subsidiary of Samsung Electronics, has announced that the Samsung GC85A DR system has received 510(k) clearance from the FDA, making it available in the U.S.

When it comes to reducing the risk of recurrence in patients with triple-negative breast cancers, pre-op MRI may be just what the doctor ordered.

Shimadzu Medical Systems USA announces the availability of T-smart, a new tomographic image reconstruction function using iterative reconstruction that improves the clarity of tomosynthesis-acquired orthopedic images containing metal implanted objects such as used in orthopedics.

A global association of imaging advocates is calling on the United Nations (UN) to make sure the value of medical technologies is reflected in the UN’s plans for sustainable development.

Rivanna Medical has announced that Accuro, the company’s handheld ultrasound device, has received FDA 510(k) clearance and can now be marketed in the U.S.

PHS Technologies Group LLC, a division of PACSHealth, LLC, a developer of innovative software that records and analyzes ionizing radiation data from medical imaging procedures, announced today that it will integrate VirtualDose™CT software from Virtual Phantoms Inc. into their industry leading dose monitoring product DoseMonitor®.

Last week, a study published in JAMA Internal Medicine added fuel to the fire in the contentious debate surrounding overdiagnosis in mammography screening. As anyone who has followed this discussion in recent years might expect, there has been some pushback.